I've been spending a lot of time lately thinking about where AI actually earns its keep beyond chatbots and code refactors. A new video piece over on MSN covers the overlap between artificial intelligence and biotechnology, decoding biological mysteries to the idea of resurrecting extinct species.

Some of this groundwork is already well established. CRISPR gave us molecular scissors. Synthetic biology gave us the assembly line. What AI adds is the ability to actually read the blueprint. Protein folding was the early proof of concept. DeepMind's AlphaFold predicts accurate protein structures with high precision from amino acid sequences, and that shifted how an entire field operates. It didn't solve every open question in structural biology, but it collapsed a problem that used to take months of lab work into something you can query computationally. Now researchers are using similar deep learning architectures to model gene regulatory networks, predict how genetic edits ripple through an organism, and design entirely new biological pathways that don't exist in nature.

As I wrote last week, I think biotech companies should treat public scrutiny like a pull request. Be transparent. Show the diffs. Any work that touches on resurrecting extinct species is going to need that energy more than almost anything else, because it sits at a weird intersection of genuinely cool science and enormous ethical baggage.

What I keep coming back to is the scale problem. Biology generates staggering amounts of data. A single human genome runs about 3 billion base pairs, according to the National Human Genome Research Institute. Multiply that across populations, across species, across environmental conditions, and you need serious computational horsepower to find signal in the noise. AI is the only tool that can keep up.

The MSN video is worth watching if you want a grounded overview of where this field actually stands versus the hype. The machine learning infrastructure being built to pursue these goals, from protein modeling to synthetic pathway design, will spill over into conservation biology, medicine, and materials science. That return on investment is what I'm watching most closely.